FibroBiologics, Inc. Common Stock (FBLG) vs Vivos Therapeutics, Inc. (VVOS)
A side-by-side comparison of FibroBiologics, Inc. Common Stock and Vivos Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FBLG
FibroBiologics, Inc. Common Stock
$1.13HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
VVOS
Vivos Therapeutics, Inc.
$0.15HealthcareDelayed quote: Oct 6, 2026, 3:50 PM EDT
Total return — FBLG vs VVOS
growth of $100 · dividends reinvested · last 3yFBLG -99.8% (-87.3%/yr)VVOS -98.0% (-72.7%/yr)VVOS compounded faster over this window
Log scale — wide-divergence pair
FBLG VVOS
FBLG vs VVOS: by the numbers
- •FBLG is the larger company ($2M vs $2M market cap).
- •Both run net losses; FBLG's is the smaller (0.00% vs -122.42% net margin).
Metrics side by side
Valuation
| Metric | FBLG | VVOS |
|---|---|---|
| P/S ratio | N/A | 0.10 |
| P/B ratio | 0.51 | N/A |
Profitability
| Metric | FBLG | VVOS |
|---|---|---|
| Gross margin | 0.00% | 59.72% |
| Operating margin | 0.00% | -107.92% |
| Net margin | 0.00% | -122.42% |
| ROE | -391.26% | N/A |
| ROIC | -286.46% | -182.30% |
Growth (annualized)
| Metric | FBLG | VVOS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 7.52% |
| Total return CAGR (5Y) | N/A | -72.60% |
Go deeper
Dig into the metrics
FibroBiologics, Inc. Common Stock ROEVivos Therapeutics ROEFibroBiologics, Inc. Common Stock operating marginVivos Therapeutics operating marginFibroBiologics, Inc. Common Stock revenue growthVivos Therapeutics revenue growthFibroBiologics, Inc. Common Stock free cash flowVivos Therapeutics free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.